Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Nuevolution Announces Formation of Strong Scientific Advisory Panel

Published: Thursday, March 14, 2013
Last Updated: Wednesday, March 13, 2013
Bookmark and Share
Company teams with scientific advisors to assist the progression of its internal drug discovery programs.

Nuevolution teams with key scientific advisors to assist the progression of its internal drug discovery programs within Inflammation and Oncology.

In June 2012, Nuevolution has announced the closing of a new financing round, and the plans to initiate internal drug discovery efforts.

Since then, Nuevolution has prioritized more than 30 high-value challenging targets for screening, which has been initiated.

The target prioritization and further program decisions have been made in close collaboration with the newly appointed advisors.

Professor Sir Marc Feldmann, Kennedy Institute, UK. Dr. Feldmann is a world-renowned scientist within immunology and a special interest in the fields of autoimmune diseases and the roles of cytokines.

He is recipient of numerous honors and awards over the years and has pioneered the work on the development of antibodies against TNFα for the treatment of RA.

Professor Dr. Gordon B. Mills, MD Anderson Cancer Center, US. Dr. Mills is a world-leading scientist within oncology and professor and chair in the Department of Systems Biology in the Division of Cancer Medicine at the MD Anderson Cancer Center, where he holds the Olga Keith Wiess Distinguished University Chair in Cancer Medicine.

Dr. Mills is co-director of the Sheikh Khalifa bin Zayed Al Nahyan Institute for Personalized Cancer Therapy and director Kleberg Center for Molecular Markers.

He also serves as advisor for pre-clinical and clinical oncology studies supporting numerous pharmaceutical- and biotechnology companies.

Dr. Alan Collis, formerly Novartis and Aventis, US. Dr. Collis has 25 years of industry experience. He has a very strong track-record within chemistry, DMPK studies and pre-clinical candidate development.

He has served as head of section within oncology at Novartis and as a central member of their Oncology and Exploratory Chemistry leadership team.

At Aventis he served at their Review Board involved with recommendations from target selection through to phase IIb initiation within inflammation and CNS diseases.

“We are obviously delighted to receive support from such a strong and experienced advisory team to help us leverage our Chemetics® technology platform and plan and promote our own pipeline” said Thomas Franch, CSO of Nuevolution.

Franch continued, “We look forward to working with Marc, Gordon and Alan and we are confident that they will help accelerate our discovery projects and provide substantial value to our programs.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Dr. Jeanette Wood Joins Nuevolution
Jeanette joins the Company as director and senior scientific advisor to the board of directors.
Tuesday, September 22, 2015
Nuevolution Appoints Henrik Simonsen
Former Director of Life Science Corporate Finance at SEB joins as its Chief Financial Officer.
Thursday, September 17, 2015
Professor Paul Workman Joins Nuevolution as Scientific Advisor
Professor Workman brings a vast knowledge and expertise within the oncology field.
Friday, July 11, 2014
Brian Zambrowicz Joins Nuevolution as Director and Senior Scientific Advisor
Company also announces other Board of Directors.
Thursday, May 22, 2014
Nuevolution, Merck License Agreement
Agreement for small molecule compounds targeting an undisclosed intracellular target for use as leads in Merck’s drug discovery and development.
Friday, February 21, 2014
Nuevolution Announces Technology Licensing Agreement
Agreement with Novartis for use of Nuevolution’s Chemetics® technology.
Friday, January 10, 2014
Nuevolution Appoints Ton Berkien as Chief Business Officer
Ton Berkien will join the company on January 1, 2014.
Tuesday, December 10, 2013
Nuevolution A/S Raises € 11 Million in New Financing Round
New financing round will enable Nuevolution to transform its current business model.
Friday, June 22, 2012
Nuevolution Announces Collaboration in Drug Discovery with Boehringer Ingelheim
Partnership to use Nuevolution's Chemetics® technology for lead discovery.
Wednesday, September 21, 2011
Nuevolution Enters Lead Discovery Collaboration in the Field of Epigenetic Disorders
A consortium has been established with the objective of identifying and developing novel small molecule drugs against epigenetic factors.
Thursday, October 07, 2010
Scientific News
Genetic Defences of Bacteria Don’t Aid Antibiotic Resistance
Genetic responses to the stresses caused by antibiotics don’t help bacteria to evolve a resistance to the medications, according to a new study by Oxford University researchers.
Detecting HIV Diagnostic Antibodies with DNA Nanomachines
New research may revolutionize the slow, cumbersome and expensive process of detecting the antibodies that can help with the diagnosis of infectious and auto-immune diseases such as rheumatoid arthritis and HIV.
Snapshot Turns T Cell Immunology on its Head
New research may have implications for 1 diabetes sufferers.
Tolerant Immune System Increases Cancer Risk
Researchers have found that individuals with high immunoCRIT ratios may have an increased risk of developing certain cancers.
Developing a Gel that Mimics Human Breast for Cancer Research
Scientists at the Universities of Manchester and Nottingham have been funded to develop a gel that will match many of the biological structures of human breast tissue, to advance cancer research and reduce animal testing.
Cell's Waste Disposal System Regulates Body Clock Proteins
New way to identify interacting proteins could identify potential drug targets.
New Approach to Treating Heparin-induced Blood Disorder
A potential treatment for a serious clotting condition that can strike patients who receive heparin to treat or prevent blood clots may lie within reach by elucidating the structure of the protein complex at its root.
Horse Illness Shares Signs of Human Disease
Horses with a rare nerve condition have similar signs of disease as people with conditions such as Alzheimer’s, a study has found.
How a Molecular Motor Untangles Protein
Diseases such as Alzheimer’s, Parkinson’s and prion diseases, all involve “tangled” proteins.
Compound Doubles Up On Cancer Detection
Researchers have found that tagging a pair of markers found almost exclusively on a common brain cancer yields a cancer signal that is both more obvious and more specific to cancer.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos